DarioHealth Corp. (Nasdaq: DRIO) has published a new study in Frontiers in Endocrinology, demonstrating the effectiveness of its cardiometabolic solution for individuals with diabetes or prediabetes and depression. The research, involving 989 users over 12 months, reveals:
Members with depression showed higher average blood glucose (BG) levels than those without
Both groups experienced significant BG decreases in the first 4 months of platform usage
A statistically significant association between depression status, BG levels, and average number of steps
Monthly average steps fully mediate the association between self-reported depression and monthly average BG
Users averaging over 400 steps daily showed significant decreases in monthly average BG